Production (Stage)
Acumen Pharmaceuticals, Inc.
ABOS
$1.02
-$0.01-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.50% | -24.82% | -44.93% | -38.08% | 9.84% |
| Total Depreciation and Amortization | 2.27% | -2.22% | 0.00% | 2.27% | 12.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.00% | 20.43% | 663.74% | -82.45% | -50.38% |
| Change in Net Operating Assets | -189.55% | 120.17% | -0.82% | 192.57% | -167.18% |
| Cash from Operations | -25.38% | -10.65% | -48.66% | 7.36% | -114.81% |
| Capital Expenditure | -- | -- | 100.00% | 54.55% | 21.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.02% | 392.77% | -126.87% | 510.18% | 81.16% |
| Cash from Investing | -3.28% | 392.77% | -126.88% | 509.64% | 81.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -711.11% | -- | -- | 100.00% | 91.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 67.19% | -113.33% | 87.39% |
| Cash from Financing | -300.00% | 78.57% | 67.19% | -101.80% | -75.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -324.19% | 107.01% | -265.37% | 205.37% | 28.70% |